查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933325

全球心肌肌钙蛋白市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的分析及预测（2026-2034 年）

Cardiac Troponin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 请询问到货日

价格

心肌肌钙蛋白市场成长驱动因子

全球心肌肌钙蛋白市场正经历强劲成长，其主要驱动因素包括心血管疾病盛行率的上升、先进诊断技术的广泛应用以及对早期检测心肌损伤的日益重视。心肌肌钙蛋白是一种高度特异性的生物标记物，用于诊断心肌梗塞 (MI) 和急性冠状动脉综合症 (ACS)。它能够检测到最细微的心肌损伤，使其成为急诊和重症监护环境中不可或缺的工具。

预计到 2025 年，全球心肌肌钙蛋白市场规模将达到 35 亿美元。预计到2026年，市场规模将成长至37.8亿美元，到2034年将进一步扩大至71.7亿美元，2026年至2034年的复合年增长率（CAGR）为8.30%。这一稳步增长反映了全球心臟相关疾病负担的日益加重以及高灵敏度检测解决方案的不断发展。

市场驱动因素

心血管疾病（CVD）盛行率的不断上升仍然是心肌肌钙蛋白市场的主要驱动因素。根据美国疾病管制与预防中心（CDC）统计，美国每40秒就有一人发生心臟病发作，凸显了快速准确诊断工具的紧迫性。肌钙蛋白水平升高与心肌损伤直接相关，肌钙蛋白检测已成为诊断心臟病发作和监测疾病进展的标准流程。

此外，全球人口老化也显着推动了市场成长。老年人更容易罹患高血压、冠状动脉疾病和心臟衰竭等慢性疾病。人口老化加剧导致住院率上升，并增加了对心臟生物标记检测（包括肌钙蛋白检测）的需求。

市场趋势

影响市场的主要趋势包括高灵敏度肌钙蛋白检测和即时检测（POC​​）肌钙蛋白检测的日益普及。这些先进的检测方法能够更快地获得结果，并提高诊断准确性，尤其是在急诊室。高灵敏度检测可以检测到极低浓度的肌钙蛋白，从而实现心肌梗塞的早期发现，并区分急性和慢性心臟疾病。

技术进步和监管审批进一步加速了这一趋势的普及。例如，美国食品药物管理局（FDA）批准高灵敏度肌钙蛋白检测，增强了其临床接受度，并扩大了其在常规心臟诊断中的应用。

限制因子

儘管市场成长前景广阔，但传统肌钙蛋白检测的敏感度限制仍构成挑战。传统检测方法无法检测到心肌损伤早期阶段的低浓度肌钙蛋白，可能导致诊断延迟。这项限制凸显了高灵敏度检测方法的必要性，同时也阻碍了其在新技术普及率较低的地区的广泛应用。

市场区隔分析

依类型划分，市场可分为肌钙蛋白 I 和肌钙蛋白 T。肌钙蛋白 I 市场占主导地位，预计到 2026 年将占全球 73.32% 的市场占有率，这主要归功于其较高的心臟特异性以及在心肌梗塞诊断中的广泛应用。由于监管审批的增加及其在心臟衰竭筛检中作用的扩大，肌钙蛋白T市场预计将稳定成长。

依应用环境划分，市场可分为实验室检测与即时检测（POC​​）。实验室检测占最大的市场占有率，预计到2026年将达到73.68%，主要得益于其高精度和详细的定量分析。然而，由于在急诊护理和资源匮乏地区使用量的增加，即时检测 (POC) 细分市场预计将以更快的速度成长。

依最终用户划分，医院和诊所将在 2026 年占市场主导地位，市占率达 63.44%。这主要归功于患者入院人数众多以及肌钙蛋白检测在急诊心臟护理的广泛应用。

区域洞察

北美将在 2025 年引领全球心臟肌钙蛋白市场，占 41.15% 的市场占有率，并创造 14.4 亿美元的收入。该地区受益于先进的医疗基础设施、有利的报销政策以及高灵敏度检测方法的广泛应用。预计到 2026 年，美国市场规模将达到 14 亿美元。

欧洲将占第二大市场占有率，这得益于 CE 认证的高灵敏度检测方法的广泛应用以及健全的监管框架。由于心血管疾病盛行率上升、诊断基础设施不断完善以及公众意识不断增强，亚太地区预计将成为成长最快的地区。到2026年，中国、日本和印度的市场规模预计将分别达到2.8亿美元、1.9亿美元和1.4亿美元。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要国家和地区主要心血管疾病盛行率（2024/2025）
  • 心臟肌钙蛋白检测技术进展
  • 主要公司新产品发布
  • 关键产业趋势：併购、业务合作等
  • 新冠疫情的影响市场

第五章 全球心肌肌钙蛋白市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依类型划分
    • 肌钙蛋白T
    • 肌钙蛋白I
  • 市场分析、洞察与预测：依安装环境划分
    • 实验室检测
    • 即时侦测 (POC)
  • 市场分析、洞察与预测：依适应症划分
    • 心肌梗塞
    • 充血性心臟衰竭
    • 急性冠状动脉综合症
    • 其他
  • 市场分析、洞察与预测：依最终用户划分
    • 医院和诊所
    • 诊断实验室
    • 家庭医疗保健，其他
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美心肌肌钙蛋白市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲心肌肌钙蛋白市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他欧洲国家

第八章：亚太地区心肌肌钙蛋白市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 亚太其他地区

第九章：拉丁美洲心肌肌钙蛋白市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲心肌肌钙蛋白市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC) 国家
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 世界市场占有率分析(2025年)
  • 企业简介
    • F. Hoffmann-La Roche Ltd.
    • bioMerieux SA
    • Abbott
    • Siemens Healthineers AG
    • Eurolyser Diagnostica GmbH
    • QuidelOrtho(Quidel Corporation)
    • PerkinElmer Inc.
    • Beckman Coulter, Inc.(Danaher)
    • RESPONSE BIOMEDICAL
    • LifeSign LLC.
Product Code: FBI101234

Growth Factors of cardiac troponin Market

The global cardiac troponin market is witnessing robust growth, driven by the rising prevalence of cardiovascular diseases, growing adoption of advanced diagnostic technologies, and increasing emphasis on early detection of myocardial injury. Cardiac troponin is a highly specific biomarker used for the diagnosis of myocardial infarction (MI) and acute coronary syndromes (ACS). Its ability to detect even minimal cardiac muscle damage has made it an indispensable tool in emergency and critical care settings.

In 2025, the global cardiac troponin market was valued at USD 3.50 billion. The market is projected to grow to USD 3.78 billion in 2026 and further expand to USD 7.17 billion by 2034, registering a CAGR of 8.30% from 2026 to 2034. This steady expansion reflects the increasing burden of heart-related disorders worldwide and the continuous evolution of high-sensitivity testing solutions.

Market Drivers

The growing prevalence of cardiovascular diseases (CVDs) remains the primary driver of the cardiac troponin market. According to the Centers for Disease Control and Prevention (CDC), in the U.S., one person experiences a heart attack every 40 seconds, highlighting the urgent need for rapid and accurate diagnostic tools. Elevated troponin levels are directly linked to myocardial injury, making troponin testing a standard protocol for diagnosing heart attacks and monitoring disease progression.

Additionally, the aging global population is significantly contributing to market growth. Older adults are more susceptible to chronic conditions such as hypertension, coronary artery disease, and heart failure. The increasing geriatric population is driving higher hospitalization rates and demand for cardiac biomarker testing, including troponin assays.

Market Trends

A key trend shaping the market is the increasing adoption of high-sensitivity and point-of-care (POC) troponin tests. These advanced tests enable faster turnaround times and improved diagnostic accuracy, particularly in emergency departments. High-sensitivity assays can detect very low levels of troponin, allowing early identification of myocardial infarction and differentiation between acute and chronic cardiac conditions.

Technological advancements and regulatory approvals are further accelerating adoption. For instance, the U.S. FDA's approval of high-sensitivity troponin assays has strengthened their clinical acceptance and expanded their use in routine cardiac diagnostics.

Restraining Factors

Despite strong growth prospects, the market faces challenges related to the limited sensitivity of conventional troponin assays. Traditional tests may fail to detect low troponin concentrations during the early hours following myocardial injury, potentially delaying diagnosis. This limitation underscores the need for advanced high-sensitivity assays but also restricts adoption in regions with limited access to newer technologies.

Segmentation Analysis

By type, the market is segmented into troponin I and troponin T. The troponin I segment dominated the market in 2026, accounting for 73.32% of the global share, due to its high cardiac specificity and widespread use in MI diagnosis. The troponin T segment is expected to witness steady growth, supported by increasing regulatory approvals and its expanding role in heart failure screening.

Based on setting, the market is divided into laboratory testing and point-of-care testing. Laboratory testing held the largest share in 2026 at 73.68%, driven by higher accuracy and detailed quantitative analysis. However, the POC testing segment is expected to grow at a faster rate due to increasing use in emergency and resource-limited settings.

By end user, hospitals and clinics dominated the market with a 63.44% share in 2026, owing to high patient admissions and extensive use of troponin tests in emergency cardiac care.

Regional Insights

North America dominated the global cardiac troponin market in 2025, accounting for 41.15% share and generating USD 1.44 billion in revenue. The region benefits from advanced healthcare infrastructure, favorable reimbursement policies, and high adoption of high-sensitivity assays. The U.S. market is projected to reach USD 1.40 billion by 2026.

Europe held the second-largest share, supported by widespread adoption of CE-marked high-sensitivity assays and strong regulatory frameworks. Asia Pacific is anticipated to be the fastest-growing region due to rising cardiovascular disease prevalence, expanding diagnostic infrastructure, and increasing awareness. By 2026, China, Japan, and India are projected to reach USD 0.28 billion, USD 0.19 billion, and USD 0.14 billion, respectively.

Competitive Landscape

The cardiac troponin market is moderately competitive, with key players focusing on product innovation, regulatory approvals, and strategic collaborations. F. Hoffmann-La Roche Ltd. leads the market due to its strong high-sensitivity troponin portfolio. Other prominent players include Abbott, Siemens Healthineers, bioMerieux, Beckman Coulter, and QuidelOrtho.

Conclusion

The global cardiac troponin market is poised for strong and sustained growth over the forecast period, driven by the rising burden of cardiovascular diseases, expanding geriatric population, and rapid adoption of high-sensitivity and point-of-care diagnostic technologies. From a market size of USD 3.50 billion in 2025, the industry is expected to reach USD 7.17 billion by 2034. While limitations of conventional assays remain a challenge, continuous technological advancements, increasing regulatory approvals, and growing emphasis on early cardiac diagnosis are expected to unlock significant growth opportunities. Overall, cardiac troponin testing will remain a cornerstone of modern cardiovascular diagnostics worldwide.

Segmentation

By Type

  • Troponin T
  • Troponin I

By Setting

  • Laboratory Testing
  • Point-of-Care (POC) Testing

By Indication

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Others

By End User

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Homecare Settings & Others

By Region

  • North America ( By Type, By Setting, By Indication, By End User, By Country)
    • U.S.
    • Canada
  • Europe ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America ( By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, By Setting, By Indication, By End User, By Country/Sub-Region)
    • GCC
    • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Cardiovascular Diseases, By Key Countries/Regions, 2024/2025
  • 4.2. Technological Advancements in Cardiac Troponin Testing
  • 4.3. New Product Launches. By Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Troponin T
    • 5.1.2. Troponin I
  • 5.2. Market Analysis, Insights and Forecast - By Setting
    • 5.2.1. Laboratory Testing
    • 5.2.2. Point-of-Care (POC) Testing
  • 5.3. Market Analysis, Insights and Forecast - By Indication
    • 5.3.1. Myocardial Infarction
    • 5.3.2. Congestive Heart Failure
    • 5.3.3. Acute Coronary Syndrome
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By End-User
    • 5.4.1. Hospitals & Clinics
    • 5.4.2. Diagnostic Laboratories
    • 5.4.3. Homecare Settings & Others
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Troponin T
    • 6.1.2. Troponin I
  • 6.2. Market Analysis, Insights and Forecast - By Setting
    • 6.2.1. Laboratory Testing
    • 6.2.2. Point-of-Care (POC) Testing
  • 6.3. Market Analysis, Insights and Forecast - By Indication
    • 6.3.1. Myocardial Infarction
    • 6.3.2. Congestive Heart Failure
    • 6.3.3. Acute Coronary Syndrome
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By End-User
    • 6.4.1. Hospitals & Clinics
    • 6.4.2. Diagnostic Laboratories
    • 6.4.3. Homecare Settings & Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Troponin T
    • 7.1.2. Troponin I
  • 7.2. Market Analysis, Insights and Forecast - By Setting
    • 7.2.1. Laboratory Testing
    • 7.2.2. Point-of-Care (POC) Testing
  • 7.3. Market Analysis, Insights and Forecast - By Indication
    • 7.3.1. Myocardial Infarction
    • 7.3.2. Congestive Heart Failure
    • 7.3.3. Acute Coronary Syndrome
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By End-User
    • 7.4.1. Hospitals & Clinics
    • 7.4.2. Diagnostic Laboratories
    • 7.4.3. Homecare Settings & Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Rest of Europe

8. Asia Pacific Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Troponin T
    • 8.1.2. Troponin I
  • 8.2. Market Analysis, Insights and Forecast - By Setting
    • 8.2.1. Laboratory Testing
    • 8.2.2. Point-of-Care (POC) Testing
  • 8.3. Market Analysis, Insights and Forecast - By Indication
    • 8.3.1. Myocardial Infarction
    • 8.3.2. Congestive Heart Failure
    • 8.3.3. Acute Coronary Syndrome
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By End-User
    • 8.4.1. Hospitals & Clinics
    • 8.4.2. Diagnostic Laboratories
    • 8.4.3. Homecare Settings & Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. China
    • 8.5.2. India
    • 8.5.3. Japan
    • 8.5.4. Australia
    • 8.5.5. Rest of Asia Pacific

9. Latin America Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Troponin T
    • 9.1.2. Troponin I
  • 9.2. Market Analysis, Insights and Forecast - By Setting
    • 9.2.1. Laboratory Testing
    • 9.2.2. Point-of-Care (POC) Testing
  • 9.3. Market Analysis, Insights and Forecast - By Indication
    • 9.3.1. Myocardial Infarction
    • 9.3.2. Congestive Heart Failure
    • 9.3.3. Acute Coronary Syndrome
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By End-User
    • 9.4.1. Hospitals & Clinics
    • 9.4.2. Diagnostic Laboratories
    • 9.4.3. Homecare Settings & Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Cardiac Troponin Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Troponin T
    • 10.1.2. Troponin I
  • 10.2. Market Analysis, Insights and Forecast - By Setting
    • 10.2.1. Laboratory Testing
    • 10.2.2. Point-of-Care (POC) Testing
  • 10.3. Market Analysis, Insights and Forecast - By Indication
    • 10.3.1. Myocardial Infarction
    • 10.3.2. Congestive Heart Failure
    • 10.3.3. Acute Coronary Syndrome
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By End-User
    • 10.4.1. Hospitals & Clinics
    • 10.4.2. Diagnostic Laboratories
    • 10.4.3. Homecare Settings & Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. F. Hoffmann-La Roche Ltd.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. bioMerieux SA
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Abbott
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Siemens Healthineers AG
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Eurolyser Diagnostica GmbH
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. QuidelOrtho (Quidel Corporation)
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. PerkinElmer Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Beckman Coulter, Inc. (Danaher)
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. financials (Based on Availability)
    • 11.2.9. RESPONSE BIOMEDICAL
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. financials (Based on Availability)
    • 11.2.10. LifeSign LLC.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. financials (Based on Availability)

List of Tables

  • Table 1: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 3: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 4: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 5: Global Cardiac Troponin Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 7: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 8: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 9: North America Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 10: North America Cardiac Troponin Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 12: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 13: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 14: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 15: Europe Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 17: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 18: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 19: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 20: Asia Pacific Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 22: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 23: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 24: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 25: Latin America Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 27: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by Setting, 2021-2034
  • Table 28: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 29: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, by End-User, 2021-2034
  • Table 30: Middle East & Africa Cardiac Troponin Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cardiac Troponin Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cardiac Troponin Market Value Share (%), By Type, 2025 & 2034
  • Figure 3: Global Cardiac Troponin Market Value Share (%), by Setting, 2025 & 2034
  • Figure 4: Global Cardiac Troponin Market Value Share (%), by Indication, 2025 & 2034
  • Figure 5: Global Cardiac Troponin Market Value Share (%), by End-User, 2025 & 2034
  • Figure 6: Global Cardiac Troponin Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 8: North America Cardiac Troponin Market Value Share (%), By Type, 2025
  • Figure 9: North America Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 10: North America Cardiac Troponin Market Value Share (%), by Setting, 2025
  • Figure 11: North America Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 12: North America Cardiac Troponin Market Value Share (%), by Indication, 2025
  • Figure 13: North America Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 14: North America Cardiac Troponin Market Value Share (%), by End-User, 2025
  • Figure 15: North America Cardiac Troponin Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Cardiac Troponin Market Value Share (%), By Country, 2025
  • Figure 17: Europe Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 18: Europe Cardiac Troponin Market Value Share (%), By Type, 2025
  • Figure 19: Europe Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 20: Europe Cardiac Troponin Market Value Share (%), by Setting, 2025
  • Figure 21: Europe Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 22: Europe Cardiac Troponin Market Value Share (%), by Indication, 2025
  • Figure 23: Europe Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 24: Europe Cardiac Troponin Market Value Share (%), by End-User, 2025
  • Figure 25: Europe Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 28: Asia Pacific Cardiac Troponin Market Value Share (%), By Type, 2025
  • Figure 29: Asia Pacific Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 30: Asia Pacific Cardiac Troponin Market Value Share (%), by Setting, 2025
  • Figure 31: Asia Pacific Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 32: Asia Pacific Cardiac Troponin Market Value Share (%), by Indication, 2025
  • Figure 33: Asia Pacific Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 34: Asia Pacific Cardiac Troponin Market Value Share (%), by End-User, 2025
  • Figure 35: Asia Pacific Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 38: Latin America Cardiac Troponin Market Value Share (%), By Type, 2025
  • Figure 39: Latin America Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 40: Latin America Cardiac Troponin Market Value Share (%), by Setting, 2025
  • Figure 41: Latin America Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 42: Latin America Cardiac Troponin Market Value Share (%), by Indication, 2025
  • Figure 43: Latin America Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 44: Latin America Cardiac Troponin Market Value Share (%), by End-User, 2025
  • Figure 45: Latin America Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Cardiac Troponin Market Value (USD billion), By Type, 2025 & 2034
  • Figure 48: Middle East & Africa Cardiac Troponin Market Value Share (%), By Type, 2025
  • Figure 49: Middle East & Africa Cardiac Troponin Market Value (USD billion), by Setting, 2025 & 2034
  • Figure 50: Middle East & Africa Cardiac Troponin Market Value Share (%), by Setting, 2025
  • Figure 51: Middle East & Africa Cardiac Troponin Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 52: Middle East & Africa Cardiac Troponin Market Value Share (%), by Indication, 2025
  • Figure 53: Middle East & Africa Cardiac Troponin Market Value (USD billion), by End-User, 2025 & 2034
  • Figure 54: Middle East & Africa Cardiac Troponin Market Value Share (%), by End-User, 2025
  • Figure 55: Middle East & Africa Cardiac Troponin Market Value (USD billion), By Country/ Sub-region, 2025 & 2034s
  • Figure 56: Middle East & Africa Cardiac Troponin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Cardiac Troponin Market Share (%), By Company, 2025